Ongoing Assessments & Recent Research.
Easy access to our work
Acute Pain
Feb 2025Multiple Sclerosis: SPMS
Jun 2025Non-Cystic Fibrosis Bronchiectasis
Sep 2025Retinitis Pigmentosa
Apr 2025Spinal Muscular Atrophy
Aug 2025Featured News & Insights.
Learn about our latest work.
Institute for Clinical and Economic Review Publishes Final Evidence Report on Treatment for Acute Pain
Independent appraisal committee vote was split on the net health benefit of suzetrigine compared to non-systemic therapies; suzetrigine has potential to be cost-saving due to avoided future cases of opioid use disorder.
03/31/2025Institute for Clinical and Economic Review Publishes Evidence Report on Treatment for Retinitis Pigmentosa
There are significant uncertainties regarding long term efficacy and durability of sonpiretigene isteparvovec; ICER estimates that treatment would achieve common thresholds of cost-effectiveness if priced between $67,400 and $101,300.
03/26/2025Health Economics Methods Advisory Group Selects First Area for Study: Assessing Treatment Benefits Appropriate to Consider in HTA Decision-Making
The Health Economics Methods Advisory (HEMA) group will conduct an assessment of the benefits of treatment that are appropriate to consider in health technology assessment.
03/18/2025Our Origin Story.
Dr. Steve Pearson explains why he founded an organization to advance the use of evidence to improve health care affordability and access for all patients and their families.
The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $500 million
Engaged with over 400 patient groups and patient reps
In a landmark international program, HTA agencies around the world can now access ICER’s customizable COVID-19 Cost-Effectiveness Model
Key
Developments.
The ICER-developed Clinical trial Diversity Rating (CDR) Tool presents a framework for evaluating the demographic diversity of clinical trial populations in a consistent, transparent manner leading to an overall diversity rating. Learn more.
The USA-based Institute for Clinical and Economic Review (ICER), England’s National Institute for Health and Care Excellence (NICE), and Canada’s Drug Agency (CDA-AMC) announced the formation of the Health Economics Methods Advisory (HEMA) initiative. Learn more.
The ICER Patient Council met in 2024 to discuss ICER’s patient engagement activities over the last year and to make an action plan for the next 12 months. One output of that meeting was the ICER Patient Council Progress Report, which describes the various projects the Council has reviewed and advised to enhance ICER’s Patient Engagement Program.
Current
Policy Papers.
Easy access to our latest policy papers
Special Report on COPD Therapies as Part of CMS Public Comment Process on Medicare Drug Price Negotiations
ICER developed a special report for CMS on two therapies in high demand for treating chronic obstructive pulmonary disease (COPD). This report was submitted to CMS as part of the 2025 public comment process defined in CMS guidance on Medicare Drug Price Negotiations for price applicability year 2027.
Barriers to Fair Access
ICER’s fourth annual “Barriers to Fair Access” assessment of prescription drug coverage policies within US commercial insurance, and the Veterans Health Administration. The analysis found that major payer coverage policies for 11 drugs often met fair access criteria for cost sharing, clinical eligibility, step therapy, and provider restrictions.
However, the report’s findings suggest that major improvements are needed in the transparency of coverage policy information for consumers, and in detailing out-of-pocket costs for patients.
Unsupported Price Increases
Of 10 high-expenditure drugs that had substantial 2023 net price increases, five were not supported by new clinical evidence; these increases accounted for $815 million in additional costs in 2023.The five drugs with unsupported price increases are Biktarvy, Darzalex, Entresto, Cabometyx, and Xeljanz.